TSE Systems
Buyout · Germany · 2019
Company
TSE Systems GmbH is a global technology leader in highly automated measurement and analysis systems for preclinical pharmaceutical research, with headquarters in Germany and the United States.
In the fields of metabolic research, behavioral research, and telemetry, TSE’s products support cutting-edge research in the fight against diabetes, high blood pressure, dementia, and schizophrenia, among other conditions. The modular hardware and software platforms—”Made in Germany”—are leaders in data generation, automation, and animal welfare. Customers include universities, research institutes, and pharmaceutical companies worldwide.
Managing Director: Leonhard von Harrach
Reason for the Investment
100% Acquisition of Shares in 2019
In August 2019, COI Partners acquired TSE Systems GmbH as part of a succession plan to accelerate the company’s continued growth and strengthen its market position.
Key Figures
0
Year Founded
Buyout
Transaction Type
Contact Person at COI
Dr. Farsin Yadegardjam has been with TSE Systems since joining the company in 2019:
“Preclinical pharmaceutical research is a structurally growing market driven by global megatrends including the rising prevalence of metabolic diseases and increasing R&D budgets. TSE Systems is exactly the kind of company we are looking for: profitable, a technology leader, and with a clear growth path that we could pursue together.”
"The desire to shape the future
is not a matter of industry.
It's a mindset."
Investments
Learn more about our portfolio.
Here you will find an overview focusing on our active portfolio companies and the background information on our investments. We are proud to have made more than 100 initial and follow-on investments over the past 25 years.
